title: IL-27 in tumor immunity and immunotherapy.
abstract: Inflammation has a central role in cancer progression. Metastatic tumors arise at sites of chronic inflammation, and tumors or tumor-infiltrating immune cells produce inflammatory mediators. By contrast, natural killer (NK) cells and cytotoxic T cells (CTLs) help eliminate premalignant lesions and limit the rate of tumor metastasis. Interleukin (IL)-27 is an IL-12 family cytokine chiefly produced by antigen-presenting cells (APCs) such as dendritic cells (DCs) and macrophages, and alone or in combination with other cytokines, IL-27 boosts antitumor immunity by contributing to the development of NK cells and CTLs - a central immnunomodulatory effect - and by exerting potent antiangiogenic and antimetastatic activities, a local antitumor effect. In this review, we argue that by virtue of its rate-limiting functions in innate and adaptive immune responses, modulating IL-27 holds considerable promise for future cancer immunotherapy.
authors.affiliation: Centre for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston 02115, MA, USA. mgopal@rics.bwh.harvard.edu
authors.forename: Gopal
authors.initials: G
authors.lastname: Murugaiyan
authors.forename: Bhaskar
authors.initials: B
authors.lastname: Saha
mesh_terms: D056704:Adaptive Immunity; D000818:Animals; D006801:Humans; D007113:Immunity, Innate; D007165:Immunosuppression Therapy; D007167:Immunotherapy; D007249:Inflammation / Q000276:immunology; D020381:Interleukin-17 / Q000276:immunology* / Q000378:metabolism; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000276:immunology / Q000378:metabolism; D018123:Receptors, Interleukin / Q000276:immunology / Q000378:metabolism; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
chemical_list: D020381:Interleukin-17; D018123:Receptors, Interleukin